STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Line 1	Title
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Line 27-56	Abstract Section
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Line 71-80	Introduction Section
Objectives	3	State specific objectives, including any prespecified hypotheses	Line 81-93	Introduction Section
Methods				
Study design	4	Present key elements of study design early in the paper	Line 102-103	Methods Section
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Line 98-112	Methods Section; 1. Data source and study population
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Line 106-112	Methods Section; 1. Data source and study population.
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	N.A. = No matched cohort was included	N.A. = No matched cohort was included
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Line 125-136	Methods Section; 3. Definition of POI.
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Line 113-124	Methods Section; 2. Data Extraction.
Bias	9	Describe any efforts to address potential sources of bias	Line 113-124	Methods Section; 2. Data
Study size	10	Explain how the study size was arrived at	Line 113-124	Methods Section; 2. Data
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Line 206-216	Methods Section; 7. Statistical methodology.

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Line 206-216	Methods Section; 7.
		(b) Describe any methods used to examine subgroups and interactions	Line 206-216	Methods Section; 7.
		(c) Explain how missing data were addressed	Line 114-115	Methods Section; 2. Data
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	Line 245-247	Result; 1. Baseline characteristics and univariate analysis results
		(e) Describe any sensitivity analyses	Line 206-216	Methods Section; 7.
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Line 102-103; Line 245-247	Methods Section; 1. Data source and study population; Result; 1
		(b) Give reasons for non-participation at each stage	Line 245-247	Result; 1. Baseline
		(c) Consider use of a flow diagram	N.A. = Patients who did	N.A. = Patients who did
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Line 251-252; Table 1	Result; 1. Baseline characteristics and univariate analysis results
		(b) Indicate number of participants with missing data for each variable of interest	N.A. = participants with	N.A. = participants with
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	N.A. = Follow up was not	N.A. = Follow up was not
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	Line 260-278	Result; 2. Multivariate
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N.A. = this is not a	N.A. = this is not a
		Cross-sectional study—Report numbers of outcome events or summary measures	N.A. = this is not a	N.A. = this is not a
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Line 260-278	Result; 2. Multivariate Analysis results and points-based prediction
		(b) Report category boundaries when continuous variables were categorized	Line 219-259; Table 1	Result; 1. Baseline
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Line 260-278	Result; 2. Multivariate
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Line 260-278	Result; 2. Multivariate
Discussion				
Key results	18	Summarise key results with reference to study objectives	Line 288-289	Discussion Section
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Line 445-464	Limitation

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Line 467-472	Conclusion
Generalisability	21	Discuss the generalisability (external validity) of the study results	Line 274-278	Result; 2. Multivariate
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Line 478	Acknowledgments

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article Information: http://dx.doi.org/10.21037/tau-21-112
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.